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Abstract
Glioblastoma differ from many other tumors in the sense that they grow infil-
tratively into the brain tissue instead of forming a solid tumor mass with a defined
boundary. Only the part of the tumor with high tumor cell density can be local-
ized through imaging directly. In contrast, brain tissue infiltrated by tumor cells
at low density appears normal on current imaging modalities. In current clinical
practice, a uniform margin, typically two centimeters, is applied to account for
microscopic spread of disease that is not directly assessable through imaging.
The current treatment planning procedure can potentially be improved by ac-
counting for the anisotropy of tumor growth, which arises from different factors:
Anatomical barriers such as the falx cerebri represent boundaries for migrating
tumor cells. In addition, tumor cells primarily spread in white matter and infil-
trate gray matter at lower rate. We investigate the use of a phenomenological
tumor growth model for treatment planning. The model is based on the Fisher-
Kolmogorov equation, which formalizes these growth characteristics and estimates
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the spatial distribution of tumor cells in normal appearing regions of the brain.
The target volume for radiotherapy planning can be defined as an isoline of the
simulated tumor cell density.
This paper analyzes the model with respect to implications for target volume
definition and identifies its most critical components. A retrospective study in-
volving 10 glioblastoma patients treated at our institution has been performed.
To illustrate the main findings of the study, a detailed case study is presented for
a glioblastoma located close to the falx. In this situation, the falx represents a
boundary for migrating tumor cells, whereas the corpus callosum provides a route
for the tumor to spread to the contralateral hemisphere. We further discuss the
sensitivity of the model with respect to the input parameters. Correct segmenta-
tion of the brain appears to be the most crucial model input. We conclude that
the tumor growth model provides a method to account for anisotropic growth
patterns of glioma, and may therefore provide a tool to make target delineation
more objective and automated.
1 Introduction
Gliomas are the most common primary brain tumors. For glioblastoma, the most ag-
gressive form, median survival is a little more than one year after diagnosis, despite
treatment schedules combining surgery, external beam radiotherapy, and chemotherapy.
The clinical experience suggests that improvements in radiotherapy alone will not lead
to patient cure. On the other hand, radiotherapy is the single most effective therapy.
Hence, the benefit of radiotherapy to prolong survival is undoubted [1, 2, 3]. Conse-
quently, we hypothesize that better targeting of the radiation can improve the efficacy
of radiotherapy and lead to prolonged survival or reduced side effects.
Glioblastoma differ from many solid tumors in the sense that they grow infiltratively.
Instead of forming a solid tumor mass with a defined boundary, glioblastoma are char-
acterized by a smooth gradient of the tumor cell density. It is well known that tumor
cells infiltrate the adjacent brain tissue and can be found several centimeters beyond the
enhancing tumor mass that is visible on MRI [4, 5, 6]. Functional imaging modalities
including amino acid Positron Emission Tomography (PET), including FET (Fluoro-
Ethyl-Tyrosine) and MET (Methionine) [7, 8, 9, 10], have potential to improve the
definition of the gross tumor volume. However, these modalities also fail to identify
areas of low tumor cell infiltration.
In current practice, radiotherapy planning is typically based on the gross tumor vol-
ume (GTV) visible on MRI. Many practitioners account for the infiltrative growth by
expanding the GTV with a 1-3 centimeter margin to form the clinical target volume
(CTV), which is irradiated to a homogeneous dose of 60 Gy. The current treatment
planning procedure can potentially be improved by accounting for two growth charac-
teristics of gliomas that are currently not or not consistently incorporated in treatment
planning:
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• An anisotropic growth of gliomas. MRI data as well as histological analysis af-
ter autopsy or resection shows that glioma growth is anisotropic [11, 12]. This
accounts for the complex shapes of the visible tumor and is due to mainly three
aspects:
- Anatomical boundaries: The dura, including its extensions falx cerebri and
tentorium cerebelli, represents a boundary for migrating tumor cells. Also,
except for rare cases of CSF seeding, gliomas do not infiltrate the ventricles.
- Tumor cells infiltrate gray matter much less than white matter.
- Tumor cells seem to migrate primarily along white matter fiber tracts.
• A spatially varying tumor cell density. Most gliomas lack a defined boundary and
tumor cells can be found several centimeters away from the T1 contrast enhancing
tumor and outside of the peritumoral edema visible on T2. The tumor is rather
characterized by a continuous fall-off of the tumor cell density [4, 5].
These macroscopic growth characteristics are partly known from histopathological anal-
ysis after autopsy or resection. A comprehensive review can be found in [12]. Math-
ematically, these macroscopic patterns of tumor evolution can be modeled by partial
differential equations of reaction-diffusion type. In one of the most popular models, the
Fisher-Kolmogorov model, tumor growth is described via two processes: local prolifer-
ation of tumor cells and migration into neighboring tissue [13]. The anisotropic growth
due to anatomical boundaries and reduced gray matter infiltration is considered via a
segmentation of the brain into white matter, gray matter and cerebrospinal fluid (CSF).
Preferential spread of tumor cells along white matter fibers can be modeled based on a
cell diffusion tensor derived from Diffusion Tensor Imaging (DTI) [14, 15]. This leads
to a phenomenological tumor growth model that estimates the spatial distribution of
tumor cells in the brain tissue in regions that appear normal using current imaging
modalities. Incorporating the tumor growth model into radiotherapy planning can be
approached in three steps:
• The shape of the target volume is modified as to match an isoline of the simulated
tumor cell density while the total volume is kept identical to the conventional
target based on an isotropic margin.
• The prescription dose within the target is redistributed based on the varying tumor
cell density, in order to deliver less dose to regions of low tumor cell density, and
(possibly) boost the regions with high tumor cell density.
• Unavoidable dose outside the target is pushed into regions that are more likely to
be infiltrated by tumor cells.
This paper primarily addresses the first aspect, i.e. the use of the tumor growth model
for automatic delineation of a radiotherapy target volume, taking into account spatial
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growth characteristics. An accompanying paper [16] discusses the implications of the
model for redistribution of dose, i.e. the second aspect.
1.1 Previous work on the Fisher-Kolmogorov glioma model
The Fisher-Kolmogorov model has been found to reproduce a wide range of glioma
growth characteristics at a macroscopic scale. For a review regarding the development of
the model see for example [13]. The mathematical properties of the Fisher-Kolmogorov
equations are discussed in detail in [17] and [18]. A clinical application involves the
personalization of the model to the patient specific anatomy (see e.g. [19] for a review).
In addition, approaches to estimate of model parameters from imaging data have been
proposed [13, 20, 21], which are based on estimating the velocity of tumor growth and
the steepness of the cell density fall-off. The velocity of tumor growth can be estimated
from a sequence of MRI images [20]; estimating the steepness of the tumor density
fall-off is based on comparing the size of the contrast enhancing tumor core to the
size of the peritumoral edema. These observable quantities relate to the generic model
parameters proliferation rate and diffusion coefficient. The model has, in particular,
been used in life time prediction [22, 23]. In addition, several extensions of the model
have been suggested. Those extensions integrate diffusion tensor imaging [14, 15], tumor
hypoxia [24], and the effect of radiotherapy [25] and chemotherapy on the evolution of
the tumor cell density [26, 27]. The idea of utilizing the model for target definition
in radiotherapy has been suggested by several authors [28, 29, 30], who propose ways
of describing tumor infiltration beyond the visible margins of the tumor. Cobzas [28]
defines a distance metric in the brain based on DTI to describe the anisotropy in tumor
growth. Konukoglu [29] and Bondiau [30] uses a travelling wave approximation of the
full reaction diffusion model to estimate the spatial distribution of tumor cells in normal
appearing brain tissue.
1.2 Contributions and organization of this paper
Even though the Fisher-Kolmogorov model has previously been studied in the mathe-
matical biology and modeling community, an application for target delineation in clinical
practice requires further research in multiple directions. Our work uses the previously
published Fisher-Kolmogorov model and aims at characterizing the potential of the
model for a true clinical application in radiotherapy treatment planning. We aim at
developing a semi-automatic contouring tool for gliomas that is practically useful. The
contributions of this paper are as follows:
• Systematic review of model assumptions: In section 2 we provide a review
of the tumor growth model in order to systematically compile the assumptions
made to apply the model to target delineation. This includes 1) highlighting the
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qualitative features of the model that are relevant for radiotherapy planning, 2)
identify the model parameters determining those features, and 3) illustrate how
the imaging data is used to personalize the model for an application to the patient
at hand.
• Use case characterization: We provide a clear illustration of use cases of the
tumor growth model for target delineation. In section 3 we perform a detailed case
study for a tumor located in proximity to falx and corpus callosum, a situation
where it is difficult to consistently account for anatomical boundaries in a manual
delineation. In A, we show results for 4 additional cases with varying tumor
location. The presented results illustrate the main findings from a study involving
10 glioblastoma patients previously treated at our institution.
• Sensitivity analysis: We discuss the sensitivity of the simulated tumor cell
density with respect to the model inputs (section 3.5). In particular, we highlight
the need for accurate brain segmentation into white matter, gray matter and
anatomical barriers.
• IMRT planning: We compare radiotherapy plans optimized for intensity-modulated
radiotherapy (IMRT) for model based versus manual target delineation (section
4). We illustrate to what degree differences in target delineation are translated
into differences in the delivered dose distribution.
Furthermore, for one patient we compare the model predicted tumor cell density to the
spatial growth patterns of the recurrent tumor (section 5). Finally, section 6 discusses
the scope of the work and the potential of a practical application of the tumor growth
model for target delineation.
2 Tumor growth calculations
The purpose of the tumor growth model amounts to estimating the density of tumor
cells in the regions of the brain that appear normal on MRI. It is assumed that the
growth of the tumor is described phenomenologically by local proliferation of tumor
cells and migration into neighboring tissue.
2.1 Patient specific input data
The tumor growth calculations are based on MR images routinely acquired in clinical
practice. The images incorporated into the simulation process are T1, T2, T2-FLAIR,
and T1 post gadolinium. The T1 post gadolinium image shows the vascularized gross
tumor volume, and the T2-FLAIR image shows the surrounding edematous region. For
illustrative purpose, these two images are shown in figure 1 for a case discussed in detail
in this paper.
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(a) (b)
Figure 1: (a) post-gadolinium T1 weighted image of a glioblastoma located in the left
parietal lobe. (b) T2-FLAIR image of the same tumor, showing the surrounding peri-
tumoral edema. (Note that the right side of the image corresponds to the left side of
the brain to follow brain imaging conventions.)
2.2 Data processing
In the first data processing step, all MR sequences are registered to the image with
highest spatial resolution. This is done using rigid registration with 6 degrees of freedom,
utilizing the function FLIRT [31] as part of the toolbox FSL [32, 33]. In the second step, a
segmentation of the brain was obtained using the multimodal brain tumor segmentation
algorithm published in [34]. The algorithm is an Expectation-Maximization (EM) based
segmentation method, which uses a probabilistic normal tissue atlas as spatial tissue
prior. For every voxel, it estimates the posterior probability for three normal tissue
classes (white matter, gray matter, and CSF1), as well as the lesion outlines on T1
post gadolinium and T2-FLAIR. The result of the EM segmentation is augmented as
described in [35] in order to facilitate a reliable identification of falx cerebri and tentorium
cerebelli as anatomical barriers. The segmentation result for the patient in figure 1
is shown in figure 2. In the last step, the reference MR image is registered to the
radiotherapy planning CT using rigid registration. The transformation matrix is saved
and later applied to register the simulated tumor cell density to the planning CT.
1In this work, we refer to all brain tissue that is neither white matter, gray matter, nor tumor as
CSF.
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Figure 2: Segmentation of the brain into contrast enhancing core (white), peritumoral
edema, white matter, gray matter, and CSF (black).
2.3 Underlying tumor growth model
It is assumed that tumor growth is described by two processes: local proliferation
of tumor cells and migration of cells into neighboring brain tissue. Mathematically,
this is formalized via the Fisher-Kolmogorov equation, a partial differential equation of
reaction-diffusion type for the tumor cell density c(r, t) as a function of location r and
time t:
∂
∂t
c(r, t) = ∇ · (D(r)∇c(r, t)) + ρc(r, t)
(
1− c(r, t)
cmax
)
(1)
where ρ is the proliferation rate which is assumed to be spatially constant, and D(r)
is the 3 × 3 diffusion tensor which depends on location r. The first term on the right
hand side of equation (1) is the diffusion term that models tumor cell migration into
neighboring tissue. The second term is a logistic growth term that describes tumor cell
proliferation. The tumor cell density c(t, r) takes values between zero and the carrying
capacity cmax. In this paper, the diffusion tensor is constructed as
D(r) =
{
Dw · I r ∈ white matter
Dg · I r ∈ gray matter (2)
where I is the 3 × 3 identity matrix, and Dg and Dw are scaling coefficients for gray
and white matter, respectively. This construction of the diffusion tensor allows for the
modeling of reduced gray matter infiltration via a different diffusion coefficient Dg < Dw.
Anatomical constraints are accounted for by boundary conditions: We assume that
tumor cells only spread in brain tissue and do not diffuse into any tissue that is not
segmented as gray or white matter. 2
2The model can be extended towards anisotropic tumor cell migration within white matter. This
is achieved by replacing the identity matrix I in equation (2) by a tensor that is constructed based on
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2.4 Qualitative features of the solution
The asymptotic solution of the Fisher-Kolmogorov equation is given by a traveling wave
solution. At the time of diagnosis, the tumor cell density takes high values close to the
carrying capacity cmax within the enhancing tumor mass seen on the post-gadolinium T1
image. This is motivated by the observation that resected tissue from this area appears
as only tumor tissue in a pathological examination [12]. At large distance from the
enhancing core, the tumor cell density approaches zero. It can be shown that, within
the traveling wave approximation, the following two properties hold:
1. The fall-off of the cell density with distance from the enhancing core is described by
a characteristic profile that remains approximately fixed while the tumor grows [17,
29]. At some distance, the tumor cell density drops approximately exponentially
with distance from the visible tumor mass. For a region comprising white matter,
the cell density behaves according to
c(|r|) ∝ exp
(
−|r|
λw
)
(3)
where |r| denotes distance from the visible tumor. The parameter λw is called the
infiltration length and denotes the distance at which the cell density drops by a
factor of e. It can be shown that λw relates to the model parameters via
λw =
√
Dw
ρ
(4)
Within gray matter the cell density drops with an infiltration length λg =
√
Dg
ρ
which is believed to be smaller than the infiltration length in white matter.
2. Over time, the tumor front moves outwards into the brain tissue at a constant
velocity. The velocity relates to the model parameters via
vw = 2
√
Dwρ (5)
In a realistic brain geometry, the propagation of the wave is spatially modulated by
anatomical boundaries and by different velocities in gray and white matter.
the water diffusion tensor obtained through DTI imaging. Although this idea has been conceptually
introduced [15, 14], it is related to several difficulties that are outside the scope of this paper. Problems
related to DTI in this context include: (1) even though histopathology provides anecdotal evidence for
preferential spread along white matter fibers, there is no data that quantitatively evaluates this effect;
(2) the DTI signal is corrupted within the edematous region where the increased water content leads to
reduced fractional anisotropy (FA) and increased apparent diffusion coefficients (ADC). In this paper,
we only consider the effects of anatomical boundaries and reduced infiltration of gray matter, because
these effects are widely agreed upon, whereas the use of DTI is more speculative at this stage.
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2.5 Relating the tumor model to imaging data
In order to apply the model to an individual patient, we have to specify how the tumor
cell density resulting from the model relates to the MR images. The contrast enhancing
region visible in the T1 post gadolinium MR image is related to a breakdown of the
blood-brain-barrier (BBB). Even though this only represents a surrogate for the tumor,
it is commonly assumed that contrast enhancing volume corresponds to the vascular-
ized, highly cellular part of the gross tumor. For this paper, we therefore assume that
the boundary of the contrast enhancing region corresponds to an isoline of the tumor
cell density close to the carrying capacity. It is used as the basis for tumor density
calculations is described in subsection 2.6.
In current clinical practice, radiotherapy planning for GBM is mostly based on structural
MRI imaging (T1 post gadolinium and T2-FLAIR). However, modern imaging modali-
ties including MR spectroscopy (MRS) and positron emission tomography (PET) have
been used for glioblastoma imaging and bear potential to improve the characterization
of gross and infiltrative disease. In particular, tracers visualizing amino acid metabolism
have been studied [7, 8, 9, 10], including FET (Fluoro-Ethyl-Tyrosine) and MET (Me-
thionine). These PET scans are not routinely acquired for glioblastoma patients at our
institution. However, if these modalities become established, the tumor growth model
could be initialized using a PET based delineation of the tumor instead of using the
contrast enhancing region.
2.6 Calculation of the tumor cell density
For treatment planning, we want to calculate the tumor cell density in the brain at
the time the MR images are taken. Using the Fisher-Kolmogorov equation directly is
problematic in that context because the initial condition, which leads to a tumor con-
sistent with the images, is unknown. One approach to circumvent this problem consists
of using the traveling wave approximation. It is assumed that, at the time of imaging,
the tumor cell density is characterized by its asymptotic solution. In this approach,
it is assumed that the tumor cell density at the T1 gadolinium outline corresponds to
an isoline of the tumor cell density. For this paper, we assume a value of 70% of the
carrying capacity. Starting at the outline, the tumor cell density is extrapolated into
the brain tissue, assuming the fall-off profile from the traveling wave approximation,
and taking into account the anatomical constraints from the brain tissue segmentation.
Mathematically, this is achieved by approximating the partial differential equation in
(1) by a static Hamilton-Jacobi equation that is solved using a Fast-Marching method.
The details of this approach are described in [29].
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Figure 3: Simulated tumor cell density based on the segmentation in figure 2 for pa-
rameters λw = 4.2 mm and Dw/Dg = 100 (a) and Dw/Dg = 10 (b) . The color scale
refers to the log10 cell density normalized to the carrying capacity.
2.7 Model parameters
The tumor growth model depends on four parameters: The diffusion coefficients in
white matter Dw and gray matter Dg, the proliferation rate ρ, and the carrying capacity
cmax. We now argue that, for our application in radiotherapy planning, the number of
parameters can be reduced to two crucial parameters.
The carrying capacity cmax can be considered as a scaling factor for the relative nor-
malized tumor cell density that takes values between zero and one. It is straightforward
to see that all results presented in this paper are independent of the value of cmax and
only depend on the relative tumor cell density. We therefore do not have to consider
the value of the carrying capacity cmax.
We are left with the model parameters Dw, Dg, and ρ. Within the traveling wave
approximation, Dw and ρ can be expressed through 1) the velocity of the tumor front
in white matter obtained from the product of Dw and ρ according to equation (5), and
2) the infiltration length in white matter obtained from the ratio of Dw and ρ according
to equation (4). In this paper, we are only interested in obtaining the distribution of
tumor cells at the time when treatment starts. Thus, we do not require the velocity of
the tumor front but only the infiltration length λw =
√
Dw/ρ. Since the tumor primarily
grows in white matter, we focus on the infiltration length in white matter instead of
gray matter. If we express the diffusion coefficient in gray matter via the ratio of white
and gray matter coefficient, we are left with two parameters of the tumor growth model:
λw =
√
Dw
ρ
: Infiltration length, describing how fast the tumor cell density drops
with distance from the visible tumor volume.
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Dw/Dg : Ratio of diffusion coefficients in white matter and gray matter, param-
eterizing in parts the anisotropy of tumor growth. The ratio of the infiltration
lengths is consequently given by λw/λg =
√
Dw/Dg.
In this paper, we are concerned with the spatial definition of the target volume as an
isoline of the tumor cell density. In that context, the exact value of the infiltration
length λw is irrelevant because it does not affect the shape of the isolines. Only the
abolute values of the tumor cell density associated with the isolines are determined by
λw
3. Thus, the only relevant model parameter for this paper is the ratio Dw/Dg, which
determines the shape of the isolines of the cell density together with the brain segmen-
tation. The literature consistently suggests that tumor cells infiltrate gray matter much
less than white matter4 This suggests a large value for Dw/Dg  1. Most illustrations
in this paper were obtained for Dw/Dg = 100. The most appropriate value is however
uncertain and we discuss the impact of uncertainties in Dw/Dg in section 3.5.
3 Model based target delineation
In this section we demonstrate the use of the tumor growth model for target definition.
In sections 3.1-3.5, we provide a detailed discussion of the patient shown in figure 1 in
order to illustrate the main findings of the study. We first compare the model-derived
target volumes to the manual delineation used in the clinical treatment plan. We then
discuss the impact of anatomical boundaries and reduced gray matter infiltration in more
detail, and finally discuss sensitivity to model inputs. We analyzed 10 GBM patients
with varying tumor locations previously treated at our institution. In section 3.6, we
summarize the main findings for these patients; further details are provided in A.
3.1 Target volume definition
Figure 4 shows the clinical target volume (dark green contour) and the boost volume
(green contour) drawn manually by the physician, i.e. these contours were the basis for
the treatment plan that was actually delivered to the patient. The prescribed dose to
the boost volume was 60 Gy, the prescribed dose to the CTV was 46 Gy. The boost
volume is defined based on a 2 cm isotropic extension of the contrast enhancing lesion.
The CTV is defined via a 1.5 cm expansion of the T2-FLAIR abnormality. Both vol-
umes were subsequently trimmed manually to account for anatomical boundaries (dura,
ventricles, falx, and tentorium cerebelli). The dose distribution of the 3D conformal
treatment plan delivered to the patient is shown in figure 6d.
3The value of λw will be crucial for dose prescription considered in the accompanying paper [16].
4This holds for the most common case of astrocytomas, not necessarily for oligodentrogliomas (see
[12] for a review of glioma growth patterns).
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Using the tumor growth model, the target volume can be defined as an isoline of the
tumor cell density. This is illustrated here for the tumor cell density shown in figure
3a obtained for the parameter value Dw/Dg = 100. The red and the orange contours
in figure 4 show the CTV and the boost volume derived from the tumor growth model,
respectively. In this example, the target defining isolines are chosen such that the total
enclosed volume is equal to the manually delineated target. In the following two sub-
sections, we discuss the differences between manual and model-derived target volumes
in detail.
Figure 4: Comparison of manually defined targets (light/dark green) and model de-
rived targets (orange/red). In the clinical treatment plan, the light green volume was
prescribed to 60 Gy, the dark green volume to 46 Gy. The yellow contour shows the
abnormality on T2-FLAIR.
3.2 Accounting for anatomical boundaries
In the manual delineation of the CTV used in the clinical plan, it is incorporated that
the falx represents an anatomical barrier for the migration of tumor cells. Hence, the
isotropic target expansion was trimmed manually. In the tumor growth model, the
falx is modeled via a layer of CSF and is automatically accounted for through the
assumption that tumor cells only migrate within white and gray matter. However, the
corpus callosum connects the two hemispheres of the brain. The tumor growth model
describes the migration of tumor cells through the corpus callosum (see figure 3 and 5a).
As a consequence, the target volume based on the growth model is extended into the
contralateral hemisphere. Figure 5a shows the tumor cell density overlaid on the coronal
T1 gadolinium image. This illustrates the three-dimensional modeling of tumor spread
via the model, including areas superior to the corpus callosum. This is not consistently
accounted for in the manual CTV. In the manually drawn target volumes, the target is
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slightly extended into the contralateral hemisphere on the slices that show the corpus
callosum, but not on the slices located superiorly and inferiorly (figure 5b). In the model
derived target volumes, the target is extended further into the contralateral hemisphere,
and the spread of tumor cells in superior-inferior direction beyond the corpus callosum
is modeled.
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Figure 5: (a) Log tumor cell density overlayed on the coronal T1 image showing spread
of the tumor in the contralateral hemisphere (λw = 4.2 mm and Dw/Dg = 100). (b)
Comparison of manual CTV (green) and model based CTV (red) (same contours as in
figure 4.
3.3 Modeling reduced infiltration of gray matter
It is typically assumed that tumor cells infiltrate gray matter much less than white
matter, which is modeled by Dw/Dg  1. In the simulated tumor cell density in figure
3, this leads to a sharp drop of the cell density towards the cortex. In most regions,
this effect does not alter the global shape of the target volume substantially because
the thickness of the cortical layer is only several millimeters. This can be seen in figure
3 in the posterior portion of the tumor. Here, the dura is essentially the boundary of
the target volume. Technically, some gray matter surrounding the fissures is outside
of the target defining isoline. However, these regions are small and are not relevant
for radiotherapy planning as further discussed in section 4. For this patient, the most
pronounced differences between the model derived target and the manually drawn target,
which can be attributed to reduced gray matter infiltration, arise in the region of the
lateral sulcus (left-anterior part of the tumor). In this region, the large amount of gray
matter surounding the lateral sulcus represents a soft barrier for migrating tumor cells.
Thus, the tumor growth model can be used to identify regions of functioning brain tissue
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that can be taken out of the target volume.
3.4 Difference in target volumes
In order to quantitatively compare the difference of manual and model-derived target
volumes, we calculate the Dice coefficient, which is given by the volume where both
structures overlap, divided by the average volume of the two structures. For the boost
and CTV volumes in figure 4 the Dice coefficients are 0.78 and 0.77, respectively. Thus,
three quarters of the manual target is also contained in the model-derived target, but a
substantial portion of approximately one quarter is different.
3.5 Sensitivity to input parameters
The model input parameters that determine the spatial distribution of tumor cells are
the segmentation of the brain (into white matter, gray matter and CSF) as well as the
parameter Dw/Dg.
Brain segmentation: Anatomical boundaries like the ventricles and the falx are mod-
eled via boundary conditions. As a consequence, correct segmentation of the brain is
a crucial input to the model. This can be illustrated for the falx: Correct modeling of
the anatomical boundary in our approach relies on identifying a layer of CSF along the
falx. If due to limitations in the automatic segmentation, the two hemispheres are con-
nected through white or gray matter bridges (outside of the corpus callosum), the falx
is not correctly established as a barrier. In this case, the growth model will incorrectly
predict interhemispherical cell migration outside of the corpus callosum. This problem
can in particular arise if, due to a tumor with mass effect, the brain tissue is compressed
and the falx is pushed towards the contralateral hemisphere. A reliable application of
the model for target definition therefore requires reliable segmentation of the ventricles
and the extensions of the dura, i.e. falx cerebri and tentorium cerebelli. In addition,
correct modeling of contralateral spread requires a reliable segmentation of the corpus
callosum as white matter. This can, for example, be problematic in the superior region
of the corpus callosum when the slice distance in the MRI scan is large. Approaches to
customize brain segmentation methods for this application can be found in [35].
Gray matter infiltration parameter: In addition to the segmentation, the ratio of
white and gray matter diffusion coefficient Dw/Dg influences the shape of the isolines
of the tumor cell density. For Dg = 0, gray matter represents a hard boundary and
tumor cells only spread in white matter. For Dw/Dg = 1, tumor cells spread equally
in white and gray matter and the shape of the target is solely influenced by anatomical
constraints. In figure 3 the simulated tumor cell density is compared for Dw/Dg = 10
and Dw/Dg = 100. For smaller Dw/Dg, the cell density is more washed out (figure 3b)
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compared to a larger Dw/Dg where the tumor cell density follows more closely the white
matter structure (figure 3a). It has been discussed above that the cortical gray matter
has a thickness of only a few millimeters. As a consequence, varying Dw/Dg has little
impact on the global shape of the target volume. The most significant changes for this
patient are around the lateral sulcus.
Interdependence: There is some interdependence regarding the sensitivity against
Dw/Dg versus segmentation errors. For small values of Dw/Dg, the result may be sen-
sitive to errors in the segmentation of CSF, whereas errors in the segmentation between
white and gray matter become irrelevant. For large values of Dw/Dg, the segmentation
of CSF becomes less crucial because falx and tentorium cerebelli are surrounded by a
layer of gray matter which models the boundary. However, errors in the segmentation
of white matter versus gray matter become more crucial.
3.6 Target volume comparison for different tumor locations
We retrospectively analysed 10 patients with varying tumor location. All patients were
treated with IMRT to a dose of 60 Gy in 30 fractions. For the clinically delivered
treatment plan, the CTV was defined using isotropic expansions of 1-2 cm to the T2-
FLAIR hyperintensity. Manual editing was performed to trim the CTV expansion where
there were clear anatomical barriers to spread such as the falx or dura. A PTV expansion
of 3 mm was added. For all patients, the tumor cell density is calculated for a parameter
value of Dw/Dg = 100 based on the method described in section 2. The model-based
target volume is defined as the isoline that encompasses the same total volume as the
manually delineated CTV used in the clinically applied plan. The main findings are
summarized as follows:
• The modeling of anatomical barriers leads to differences in the target volume for
tumors located close to corpus callosum and falx cerebri. The use of the tumor
growth model suggests a further expansion of the target into the contralateral
hemisphere.
• The modeling of reduced gray matter infiltration leads to differences in the target
volume for tumors located in proximity to major sulci. This effect was most
pronounced in the region of the lateral sulci where the use of the tumor growth
model suggests regions that can be excluded from the target volume.
• Dice coefficients between manual and model derived target volumes were calculated
for all 10 patients (table 1). The overlap between manual and model-based target
volumes was 79% on average, ranging from 74% to 84%. This indicates that
approximately 20% of the manual target volume is not contained in the model-
based volume (and vice versa).
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• For all patients IMRT treatment plans were optimized using a homogeneous 60
Gy prescription dose to the CTV and the planning formulation in section 4. Dice
coefficients for the 95% isodose lines (57 Gy) were calculated in order to compare
the differences in the high dose region between manual and model derived radiation
plans (table 1). The Dice coefficient was 0.84 on average, ranging from 0.80 to
0.87, indicating that a substantial part of the differences in target volume also
translates into differences in the high dose region.
In the appendix A, we provide details for four representative cases. These four cases
span a range of different tumor locations, i.e. GBMs in the parietal lobe, temporal lobe,
frontal lobe, and bilateral corpus callosum.
Location Dice CTV contour Dice 57 Gy isoline
1 Parietal (Fig. 4) 0.77 0.82
2 Temporal/Frontal (Fig. 8) 0.74 0.81
3 Parietal (Fig. 10) 0.81 0.82
4 Temporal (Fig. 11) 0.84 0.87
5 Corpus Callosum (Fig. 12) 0.76 0.82
6 Temporal (not shown) 0.81 0.85
7 Temporal (not shown) 0.83 0.86
8 Parietal (not shown) 0.80 0.84
9 Parietal (not shown) 0.84 0.85
10 Temporal (not shown) 0.74 0.80
Table 1: Dice coefficients for the CTV contours and the 57 Gy isoline of an IMRT plan
for different tumor locations.
3.7 Model-based target delineation without a reference volume
In figure 4 we have defined the model derived target contours such that the overall
volumes of the targets equal the volumes of the targets in the clinical plan. This has
been done for the sake of comparison of the shapes of the target volumes. In a practical
scenario, the model is used for target definition without the existence of a manually
drawn reference volume. In this case, the choice of the target defining isoline can be
performed by either specifying the target expansion in white matter, or by specifying
the average expansion:
1. In the first scenario, the treatment planner is provided with the simulated tumor
cell density together with the delineation of enhancing core and edema as well as
the brain segmentation. The treatment planner can then manually pick a target
defining isoline by measuring the distance to the enhancing core along major sheets
of white matter.
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2. In the second case, a temporary reference volume can be created automatically
as an isotropic expansion around the enhancing core, intersected with the brain
tissue mask. The model-derived target volume can then be defined as the isoline
that encompasses the same total volume as the temporary reference volume. In
this case, the treatment planner has to specify the average margin added to the
enhancing core.
4 Treatment plan comparison
In this section we illustrate the impact of the model derived target volumes on the dose
distribution. A treatment plan for intensity modulated radiotherapy was optimized,
using 9 equally spaced coplanar 6MV photon beams. Dose calculation was performed
using the Quadrant Infinite Beam (QIB) algorithm in CERR [36], and the optimization
of IMRT treatment plans was performed using our own implementation of the L-BFGS
quasi-newton method. More specifically, we minimize the following piece-wise quadratic
objective function
f(d) =
∑
η
woη
Nη
∑
i∈Vη
(
di − dmaxη
)2
+
(6)
+
wuT
NT
∑
i∈T
(dpresi − di)2+ +
woT
NT
∑
i∈T
(di − dmaxT )2+ (7)
+
woH
NH
∑
i∈H
(di − dmaxi )2+ (8)
The first term (6) denotes overdose objectives for the organs at risk (OAR). For the
maximum doses dmaxη and weighting factors w
o
η, we use the values summarized in table
2. The second term (7) represents under and over dose objectives for all target voxels.
The prescribed dose dpresi is set to 60 Gy for all voxels i in the boost volume and 46 Gy in
the CTV. The maximum dose dmaxT in all target voxels is set to 60 Gy. For all unclassified
normal tissues surrounding the target volume (including skull, brain tissue, ventricles),
we use a conformity objective in which dmaxi decreases linearly with the distance of voxel
i from the target volumes. Here, we define a generalization of the conformity objective
to the case of an inhomogeneous prescription dose. More specifically, for every voxel i
we define
dmaxi = max
[
dlow,max
j
(
dpresj − zij dgrad
)]
(9)
where zij denotes the euclidean distance of the voxel i from another voxel j that has
a non-zero prescription dose dpresj . The parameter d
grad is specified in Gy per cm and
describes the desired dose falloff in healthy tissue; dlow is a lower dose threshold below
which dose is not penalized. The optimization parameters used are summarized in table
2.
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Figure 6: Comparison of dose distributions (in units of Gy): (a) for a plan based on
manual target volumes; (b) for model-derived target volumes. The difference of the dose
distribution is shown in (c). Figure (d) shows the planned dose distribution for the 3D
conformal plan the patient was treated with.
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wo wu dmax dpres dgrad dlow
CTV 10 20 60 46 - -
Boost 10 20 60 60 - -
Brainstem 10 - 45 - - -
Optic nerves 10 - 30 - - -
Chiasm 10 - 30 - - -
Eye lenses 10 - 10 - - -
Eye balls 10 - 10 - - -
Unclassified 10 - - - 40 20
Table 2: Objective function parameters used for IMRT optimization
Figure 6 shows the dose distributions obtained for two treatment plans. The plan in
figure 6a is based on the manually drawn target volumes, whereas the plan in figure
6b is based on the target volumes derived from the growth model. For the sake of
comparison, the plan based on model-derived targets was optimized by imposing an
additional constraint on the integral dose delivered to the patient, i.e. we minimize
objective function (6-8) subject to the constraint∑
i∈V
di ≤ dint (10)
where V denotes the set of all voxels in the patient, and dint denotes the integral dose
obtained for the treatment plan based on the manual target volumes. Figure 6c shows
the difference of the plans in figures 6a and 6b. It can be seen that in plan 6b more dose
is delivered to the contralateral hemisphere. Under the constraint that integral dose is
not increased, this is compensated for by delivering less dose to other regions, e.g. near
the lateral sulcus.
To quantify the difference in dose distributions in figure 6, we calculate the Dice coeffi-
cients for the volumes enclosed by selective isodose lines. The Dice coefficients for the
57 Gy and the 46 Gy isodose line evaluate to 0.84 and 0.83, respectively. In section 3.4
we calculated the Dice coefficient between manual and model-derived boost and CTV
volumes, which are 0.78 and 0.77, respectively. It is apparent that differences in target
volumes only partly translate into differences in dose distributions. The rugged shape
of the model-derived target volume that arises from reduced infiltration of gray matter
is mostly not of relevance for radiotherapy planning. Due to the physical characteristics
of photon beams it is not possible to spare thin layers of gray matter surrounding small
fissures.
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5 Comparison to follow-up imaging
5.1 Scope
Ideally, we would like to have a way to validate the predictions of the growth model
regarding the tumor cell density. Histopathological analysis of resected brain tissue
would represent one way to validate the extent of tumor cell infiltration predicted by
the model. However, it is currently not realistic to obtain such data for untreated human
patients at high spatial resolution. Tissue samples taken from biopsies or resected tumors
may provide information at selected locations. Usually this is, however, limited to the
gross tumor volume; taking biopsy samples from healthy appearing brain tissue, which
would be relevant for target delineation, is not performed.
An alternative approach towards collecting evidence for the plausibility of the growth
model consists in evaluating the spatial progression patterns of recurrent tumors in
follow-up MRI images. The advantage of this approach is that this data is widely avail-
able since high grade glioma patients typically receive follow-up MR imaging every 2-3
months. On the downside, model validation based on follow-up imaging has limitations.
This includes the difficulty in distinguishing recurrent tumor from other radiation in-
duced changes (e.g. radiation necrosis), and the large variation in response to radiation
between patients. In addition, deformations due to surgery, tumor mass effects, and
radiation related brain atrophy may occur. Addressing these issues in their complex-
ity is outside the scope of this paper. Nevertheless, we hypothesize that the analysis
of progression patterns of recurrent tumors can provide some degree of evidence for
the plausibility of the tumor growth model. Due to the variability in treatment and
treatment response, this is not the case for all patients - but for individual cases.
5.2 Patient characteristics
The patient discussed in sections 3 and 4 only had a biopsy taken prior to radiother-
apy without significant tumor resection. Also, the patient did not receive additional
cycles of chemotherapy or antiangiogenic drugs after the initial course of chemoradia-
tion with concurrent temozolomide. Figure 7 shows two follow-up T2-FLAIR images
for this patient. The follow-up images were registered to the reference image using rigid
registration. The image in figure 7a was taken 3.5 months after the diagnostic image
(figure 1) and 2 months after completion of radiotherapy. The image in figure 7b was
taken 7.5 months after the diagnostic image, which was the last image taken before the
patient expired. Even though there is no histopathological confirmation, the radiological
appearance and the patient’s death about 9 months post therapy suggest progressive
disease rather than other radiation induced changes. Thus, for the remainder of this
section, we make the assumption that the follow-up imaging shows the progression of
the tumor. Furthermore, the tumor recurs/progresses centrally, which is the case for
the vast majority of cases given standard of care treatments. Figure 6d shows the dose
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distribution of the clinically delivered 3D conformal treatment plan.
(a) 3.5 month (b) 7.5 months
Figure 7: T2-FLAIR images acquired after therapy, overlaid with isolines of the tumor
cell density simulated on the diagnostic images prior to radiotherapy (figure 3a): (a) 3.5
month after diagnosis with isolines for tumor cell densities of 10−1, 10−2, and 10−3, and
(b) 7.5 months after diagnosis with isolines for tumor cell densities of 10−2, 10−3, and
10−4.
5.3 Comparison of follow-up images and simulated tumor in-
filtration
By considering the delivered dose distribution in figure 6d, we see that the progressive
tumor is located almost entirely within the high dose region receiving approximately
60 Gy. Under the assumption that a radiation dose of 60 Gy kills a fraction of the
tumors cells, the shape of the isolines after therapy is not altered within the high dose
region. In this case, the Fisher-Kolmogorov model predicts that the progression of
the tumor approximately follows the isolines of the tumor cell density simulated pre
therapy. This motivates to compare the simulated cell density isolines directly to the
follow-up images without explicitly modeling the effect of chemoradiation on the cell
density quantitatively.
In figure 7 we overlaid the tumor cell density simulated on the diagnostic image on the
follow-up T2-FLAIR images. It is seen that the progression of the tumor post therapy
follows the isolines of the simulated tumor cell density relatively closely. In particular,
the follow-up images show the progression of the tumor through the corpus callosum
into the contralateral hemisphere as predicted by the model. The latter is supported
by the T1 post contrast images 3.5 and 7.5 months post therapy, which show contrast
enhancement in the corpus callosum (T1 images not shown).
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6 Discussion
6.1 The problem addressed in this work
In this work, we aim at improving and automating target volume delineation for glioblas-
toma. We investigate the use of a phenomenological tumor growth model based on a
reaction-diffusion equation for the tumor cell density. The model has been studied in
the literature over the past years. Here, we aim at bringing this model closer to an appli-
cation in radiotherapy treatment planning. The problem addressed here originates from
the infiltrative growth characteristics of glioma and the fact that tumor cells infiltrate
brain tissue beyond the abnormality visible on current imaging modalities. In clinical
practice, an approximately 2 centimeter wide margin is added around the T2-FLAIR
abnormality. It is however known that glioma growth is not isotropic. Tumor growth
patterns are influenced by anatomical boundaries as well as reduced infiltration of gray
matter. Hence, adding an isotropic margin will unnecessarily expose normal tissue or
miss areas of concern. Anatomical constraints can partly be accounted for in the man-
ual definition of the CTV, e.g. by excluding ventricles and regions outside of the dura.
However, a consistent modeling of more complex 3D anatomical features is difficult to
achieve manually.
6.2 Main findings
We performed a retrospective study involving 10 GBM patients treated previously at
our institution. For these patients, we compare manually drawn target volumes used in
the clinically delivered treatment plan to model-derived target volumes defined through
an isoline of the tumor cell density. One goal of the study is to characterize the best
use cases for model based target delineation, i.e. we identify anatomical situations in
which the growth model leads to more consistent target volumes compared to manual
delineation. As demonstrated in the paper, this may be the case for tumors located in
proximity to falx and corpus callosum. In this situation, the falx represents a boundary
for migrating cells, but the corpus callosum provides a route for the tumor to spread to
the contralateral hemisphere. The tumor growth model represents a tool to automate
and objectify target definition for such cases, which is difficult to achieve manually. In
addition, it is demonstrated that modeling of reduced infiltration of gray matter may
influence target delineation near major sulci, where large accumulations of gray matter
surrounding the sulci represent a soft boundary for migrating tumor cells. In particular,
this effect is observed for tumors located in proximity to the lateral sulcus. By optimizing
IMRT treatment plans based on model-derived and manually drawn target volumes, it
is demonstrated that the differences in target delineation may translate into differences
in the delivered dose distribution.
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6.3 Scope of the work
Technical versus clinical goal: The work presented has both a technical goal and
a clinical goal. The technical goal of this project is to develop automated delineation
of the CTV while accounting for anisotropic growth patters. Currently, anatomical
barriers are to some degree taken into account manually. In complex situations, this is
a time consuming process and often leads to inconsistent CTVs. Automated GTV to
CTV expansion will greatly accelerate treatment planning and make treatment volumes
more objective. In addition to the technical goal, more accurate identification of the
highest risk regions of microscopic disease may translate into a clinical advantage. The
large isotropic CTV expansions currently used include neighboring low risk normal brain
tissue, which may receive unnecessary and potentially harmful irradiation. However, by
using smaller CTV margins, clinicians risk missing areas of tumor extension, which may
lead to earlier locoregional failure. Due to the heterogeneity among GBM patients,
the clinical advantage will be difficult to demonstrate, however, the technical goal of
automating CTV delineation is itself worthwhile to pursue.
The role of model validation: Common criticisms to the use of tumor growth mod-
els for radiotherapy planning are that models are oversimplified, that a validation of the
model based on clinical data is possible only to a limited extent, or that model pa-
rameters are unknown or uncertain. For this model, the analysis of growth patterns
of recurrent tumors may provide some indication for the plausibility of the model for
individual patients. However, further research on model validation based on follow-up
imaging, including MRI, MR Spectroscopy, and PET is needed. Nevertheless, we argue
that an application of the model may be helpful in radiotherapy target volume defi-
nition despite these limitations. The model parameterizes features of glioma growth
that are commonly agreed upon. The model can be viewed as a component in an au-
tomatic GTV to CTV expansion tool, which defines a distance measure in the brain
that accounts for the patient specific anatomy. It allows treatment planners to incorpo-
rate their belief on glioma growth characteristics in multiple stages: In the first stage,
anatomical boundaries can be accounted for, which is achieved by segmentation of the
ventricles, falx cerebri and tentorium cerebelli. This is a promising application because,
clearly, the falx represents a barrier for migrating tumor cells while the corpus callosum
allows for inter-hemispheric spread of disease. In the second stage, reduced gray matter
infiltration can be incorporated by choosing Dw/Dg > 1. If integrated into contouring
software used in clinical practice, this tool can suggest an initial target volume to the
physician, which optionally can be modified manually.
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7 Conclusions
The Fisher-Kolmogorov equation represents a model for the spatial distribution of infil-
trating tumor cells in normal appearing brain tissue. It can be applied in radiotherapy
target delineation by defining target volumes as isolines of the tumor cell density. The
model can incorporate spatial growth characteristics of infiltrating gliomas: the effect
of anatomical barriers and a reduced tumor infiltration in gray matter. Therefore, the
tumor growth model can provide the basis for an automatic contouring tool that pro-
vides the option to account for widely agreed growth patterns of glioma. The approach
appears particularly useful for tumors located close to the falx and the corpus callosum.
The most crucial input to the model is the segmentation of the brain tissue, in particular
the reliable segmentation of the anatomical barriers falx cerebri and tentorium cerebelli.
A Target volume comparison for different tumor lo-
cations
In section 3.6, we summarized the results for model based target delineation for 10 GBM
patients that were analyzed. In this appendix, we provide details on four representative
cases, which span a range of different tumor locations, i.e. GBMs in the parietal lobe,
temporal lobe, frontal lobe, and bilateral corpus callosum. The Dice coefficients between
the manual and model-derived target volumes are summarized in table 1, together with
the corresponding Dice coefficient between the 95% isodose lines of the IMRT plans.
(a) (b)
Figure 8: Multifocal GBM located in the left temporal and frontal lobe: (a) coronal T1
post contrast image; (b) axial T1 post contrast image. The manually drawn CTV is
shown in green, the model derived CTV in red.
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Figure 9: (a) Simulated tumor cell density for the patient shown in figure 8; (b-c)
Comparison of IMRT dose distributions (in units of Gy) of the plan based on manual
target volume (c) and the model-derived target volume (b). The difference of the dose
distributions is shown in (d).
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A.1 Multifocal temporal/frontal lobe case
Figure 8 shows a multifocal GBM case involving the left temporal lobe as well as the
frontal lobe. Figure 8a shows the coronal T1 post contrast image, revealing the contrast
enhancing tumor mass in the temporal lobe. The axial T1 post contrast image in figure
8b shows the lesion in the frontal lobe. The simulated tumor cell density in figure
9a illustrates several features discussed in sections 3 and 4: The tumor growth model
describes the steep fall-off of the tumor cell density in gray matter, leading to differences
in the target volume around the lateral sulcus (figure 8b). In addition, modeling tumor
cell infiltration through the corpus callosum leads to differences in the target volume
in the contralateral frontal lobe. Figure 9 shows the IMRT plan comparison for a
homogeneous 60 Gy prescription to the manual CTV (c) and the model-derived CTV
(b). The figure shows that the differences in the target volume partly translate into
differences in the dose distribution. In particular, the dose difference plot in figure 9d
shows a lower dose in the lateral sulcus region for the model-based plan, and a higher
dose in the contralateral hemisphere close to the corpus callosum.
A.2 Parietal lobe case
Figure 10a shows the T2-FLAIR image of a GBM located in the left parietal lobe.
Compared to the case discussed in section 3, the tumor is located more posteriorly and
closer to the falx. The simulated tumor cell density for Dw/Dg = 100 is shown in figure
10b. Similar to the case discussed in section 3, the tumor growth model simulates the
infiltration of the contralateral side via the corpus callosum. The comparison of model
derived target volume (red) to the manually drawn CTV (green) in figure 10a reveals
that the tumor growth model suggests further spread into the contralateral hemisphere.
(a) (b)
Figure 10: GBM located in the left parietal lobe adjacent to the falx: (a) T2-FLAIR
image with manual CTV (green) and model derived CTV (red); (b) simulated tumor
cell density.
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A.3 Temporal lobe case
Figure 11 shows a GBM located in the left temporal lobe. As for the other patients,
the ventricles and the falx represent a boundary for infiltrating tumor cells, whereas
the corpus callosum allows for contralateral spread. However, in this case, the tumor
is located relatively far from the corpus callosum. Therefore, the model based target
contour does not differ significantly from the manually drawn CTV in the region around
the midsagittal plane (figure 11b). The largest differences between manual and model
based CTV occur in the regions near the lateral sulcus, where the tumor growth model
describes the sulcus with its surrounding gray matter as a boundary (figures 11a/b).
Note that the left lateral sulcus is shifted anteriorly due to the tumor with mass effect.
(a) (b) (c)
Figure 11: GBM located in the left temporal lobe: (a) T1 post contrast image; (b)
T2-FLAIR image; (c) simulated tumor cell density. Note that (b) and (c) represent the
same slice whereas (a) is located 7.5 mm inferiorly. The manually drawn CTV is shown
in green, the model derived CTV in red.
A.4 Corpus callosum case
Figure 12 shows a GBM case involving the bilateral corpus callosum. The simulated
tumor cell density in 12c models the fall-off of the tumor cell density in the cortical
gray matter surrounding the sulci. This is most prominent in the proximity of major
sulci including the lateral sulcus and occipital lobe. The effect of reduced gray matter
infiltration leads to differences of up to approximately 1 cm between manual and model
derived CTV. In regions where the CTV extends all the way to the dura (see e.g. right
posterior region in figure 12a), the differences are insignificant because of the limited
dose gradients that can be achieved with therapeutic photon beams. However, in several
regions, differences in the CTV contours translate into dose differences in an IMRT plan.
This is visible in figure 12b, where the red contour is further expanded into the major
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fiber tracts of the corona radiata, but the ventricles and regions in the occipital lobe are
spared.
(a) (b) (c)
Figure 12: GBM located in the corpus callosum: (a) T1 post contrast image; (b) T2-
FLAIR image; (c) simulated tumor cell density. Note that (b) and (c) represent the
same slice whereas (a) is located 12.5 mm superiorly. The manually drawn CTV is
shown in green, the model derived CTV in red.
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